New Evidence Supports Chromogenic Assays After Hemophilia A Gene Therapy – JTH
Journal of Thrombosis and Haemostasis (JTH) shared on LinkedIn about a recent article by Flora Peyvandi et al, adding:
”Correlation between Factor VIII chromogenic activity and antigen levels in patients treated with adeno-associated virus 5-mediated gene therapy for hemophilia A
In four patients with severe hemophilia A, FVIII antigen levels closely matched chromogenic assay results after gene therapy, supporting it as the preferred monitoring method.”
Title: Correlation between Factor VIII chromogenic activity and antigen levels in patients treated with adeno-associated virus 5-mediated gene therapy for hemophilia A
Authors: Flora Peyvandi, Isabella Garagiola, Novembrino Cristina, Lucia Schiavone, Massimo Boscolo-Anzoletti, Alessandro Ciavarella, Vincenzo La Mura
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 2, 2026, 06:00Susan Wickersham: Gradual Shift towards Autologous Blood Transfusion is a Current Trend
-
Oct 2, 2026, 05:54Shamee Shastry: When Every Cell Reacts – The Hunt for Rare Blood
-
Oct 2, 2026, 05:49David Mclntosh: Expanding Plasma Protein Therapies in Underserved Regions
-
Oct 2, 2026, 05:38Dianne E. van der Wal: C-Terminal Endings Impact PAR1/PAR4 Peptide Potency in In Vitro Platelet Assays
-
Oct 2, 2026, 05:29Mohammed Alo: Your LDL Isn’t a Snapshot – It’s a Smoking Habit Measured in Years
-
Oct 2, 2026, 00:33Marwa Mostafa: Hemoglobinopathies – When Globin Genes Go Wrong
-
Oct 1, 2026, 23:46Behnood Bikdeli: Global Burden of Venous Thromboembolism
-
Oct 1, 2026, 23:46Sthanu Subramanian: Clinical Presentation, Risk Factors, Diagnosis, and Neuroimaging Findings in CVT
-
Oct 1, 2026, 23:45Martha Gulati: Oral MHT Is Associated With Increased Thrombotic Risk